Pharvaris N.V. (PHVS): Price and Financial Metrics
GET POWR RATINGS... FREE!
PHVS Stock Price Chart Interactive Chart >
PHVS Price/Volume Stats
| Current price | $17.49 | 52-week high | $22.00 |
| Prev. close | $18.00 | 52-week low | $13.14 |
| Day low | $17.36 | Volume | 900 |
| Day high | $17.49 | Avg. volume | 12,548 |
| 50-day MA | $17.47 | Dividend yield | N/A |
| 200-day MA | $17.05 | Market Cap | 556.88M |
Pharvaris N.V. (PHVS) Company Bio
Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.
Latest PHVS News From Around the Web
Below are the latest news stories about Pharvaris NV that investors may wish to consider to help them evaluate PHVS as an investment opportunity.
Pharvaris to Participate in 11th Annual SVB Leerink Global Healthcare ConferenceZUG, Switzerland, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually from February 14–18, 2022. The fireside chat |
Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?Here is how AllScripts Healthcare (MDRX) and Pharvaris N.V. (PHVS) have performed compared to their sector so far this year. |
Pharvaris Announces Changes to its Board of DirectorsZUG, Switzerland, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the development and commercialization of novel oral bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced the appointment of Anne Marie de Jonge Schuermans, Ph.D., to the board of directors with expected confirmation at the company’s 2022 annual general meeting of shareholders. Dr. de |
Pharvaris Reports Third Quarter 2021 Financial Results and Provides Business HighlightsRAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks, proceeding; topline data reaffirmed for 2022CHAPTER-1, Phase 2 prophylactic study of PHVS416 for the prevention of HAE attacks, recruiting; topline data expected in 2022PHVS719 Phase 1 pharmacokinetics study initiating this monthExecuting from a strong financial position with cash and cash equivalents of €218.6 million as of September 30, 2021 ZUG, Switzerland, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS |
7 Best Stocks Under $20 According to Billionaire Andreas Halvorsen’s Viking GlobalIn this article, we take a look at the 7 best stocks under $20 according to billionaire Andreas Halvorsen’s Viking Global. If you want to skip our detailed analysis of Andreas Halvorsen’s hedge fund performance, early life, and biography, skip ahead to the 3 Best Stocks Under $20 According to Billionaire Andreas Halvorsen’s Viking Global. […] |
PHVS Price Returns
| 1-mo | 2.34% |
| 3-mo | 2.28% |
| 6-mo | 18.90% |
| 1-year | -14.68% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 21.54% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...